| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18317 R77149 |
Chan (Controls unexposed, sick), 2024 | Respiratory system malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Monotherapy: SSRI only Unexposed sick: old history of illness/treatment (> 12 months before pregnancy) or not specified | 2.17 [0.13;36.58] C | 0/66 15/4,413 | 15 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18315 R77125 |
Chan - SNRI (Controls exposed to TCA), 2024 | Respiratory system malformations | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: SNRI only |
0.84 [0.04;17.58] C excluded (control group) |
0/77 2/322 | 2 | 77 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18316 R77137 |
Chan - SNRI (Controls unexposed, general pop), 2024 | Respiratory system malformations | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: No Monotherapy: SNRI only |
2.50 [0.15;40.36] C excluded (control group) |
0/77 1,205/462,377 | 1,205 | 77 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15171 R62283 |
Benevent - SNRI, 2023 | Respiratory system anomalies | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: SNRI only | 6.24 [0.38;101.91] C | 0/314 37/146,855 | 37 | 314 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11684 R42950 |
Ankarfeldt a - Duloxetine (Controls unexposed, NOS), 2021 | Respiratory malformations | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
0.92 [0.26;3.24] excluded (control group) |
-/1,438 13/5,751 | - | 1,438 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11685 R42966 |
Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 | Respiratory malformations | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 1.50 [0.25;8.98] | -/1,434 -/1,435 | - | 1,434 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11745 R43132 |
Huybrechts - Duloxetine (Controls unexposed, NOS), 2020 | Respiratory malformations | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
0.87 [0.39;1.94] excluded (control group) |
-/2,532 -/- | - | 2,532 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11746 R43146 |
Huybrechts - Duloxetine (Controls unexposed, sick), 2020 | Respiratory malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.89 [0.29;2.75] | -/2,532 -/2,456 | - | 2,532 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11696 R43027 |
Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 | Respiratory system malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: SNRI only Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 2.17 [1.07;4.38] | -/738 -/14,847 | - | 738 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.77 [1.03;3.05] | 52 | 5,084 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick; 4: Controls unexposed, sick;
Asymetry test p-value = 0.8503 (by Egger's regression)
slope=0.4777 (0.5238); intercept=0.1732 (0.8428); t=0.2056; p=0.8503
excluded 11745, 11684, 18315, 18316